FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
EHA 2024 preview – Shattuck has a heart scare
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
FDA critics barely lay a glove on Geron
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
Seven problems for Geron
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
